Full Signal Bullish stocks NO ONE talks about! | Lou Basenese
14 snips
Mar 3, 2026 
Lou Basenese, veteran market strategist and founder of The Big Skinny, shares high-conviction sector calls. He discusses AI-driven market confusion and why NVIDIA stands out. He highlights contrarian buys in biotech, energy, and small caps. He also singles out Halozyme, defends Apple’s steady role, and maps winners in the GLP-1 wave.
AI Snips
Chapters
Transcript
Episode notes
Layoffs Reflect Right-Sizing Not Just AI
- Large tech layoffs often reflect over-hiring from boom times and management inefficiency, not purely AI-driven displacement.
- Lou compares Block's cuts to X's post-acquisition trimming where functionality largely persisted despite massive staff cuts.
Patent Cliff Will Drive Biotech M&A Demand
- Big Pharma faces $170–180B of revenues losing patent protection through 2028, creating urgent demand for external innovation.
- That drives acquisitions of small biotechs as pipelines can't be rebuilt quickly; many biotech names trade cheap relative to cash.
Use XBI ETF To Play Biotech If You Are Risk Averse
- Use XBI ETF for broad biotech exposure if unfamiliar with binary clinical risk.
- Individual biotechs swing on trial data and cash runway, so ETFs offer safer, diversified participation.